{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:12:55Z","timestamp":1792548775229,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-55408-2","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:47:44Z","timestamp":1735850864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3163-8685","authenticated-orcid":false,"given":"Brandon","family":"Zimmerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Nanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Blasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1777-8751","authenticated-orcid":false,"given":"Marissa","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5073-2670","authenticated-orcid":false,"given":"Tiansheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suganthini","family":"Nanthakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizelle","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caline","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Matsye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7698-8201","authenticated-orcid":false,"given":"Guanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3840-0195","authenticated-orcid":false,"given":"Harsha","family":"Swamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Bright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvarna","family":"Khare-Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-5329","authenticated-orcid":false,"given":"Niresh","family":"Hariparsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Proctor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2766-8353","authenticated-orcid":false,"given":"Timothy","family":"Senter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinley","family":"Furey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6063-8041","authenticated-orcid":false,"given":"Mark E.","family":"Bunnage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"55408_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2215\/CJN.15161219","volume":"16","author":"DJ Friedman","year":"2021","unstructured":"Friedman, D. J. & Pollak, M. R. APOL1 Nephropathy: From Genetics to Clinical Applications. Clin. J. Am. Soc. Nephrol. 16, 294\u2013303 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"55408_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/ki.2012.263","volume":"83","author":"MS Lipkowitz","year":"2013","unstructured":"Lipkowitz, M. S. et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83, 114\u2013120 (2013).","journal-title":"Kidney Int"},{"key":"55408_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1681\/ASN.2011040388","volume":"22","author":"JB Kopp","year":"2011","unstructured":"Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129\u20132137 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55408_CR4","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","volume":"369","author":"A Parsa","year":"2013","unstructured":"Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183\u20132196 (2013).","journal-title":"N. Engl. J. Med."},{"key":"55408_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2215\/CJN.0000000000000070","volume":"18","author":"DP Chen","year":"2023","unstructured":"Chen, D. P. et al. Kidney Disease Progression in Membranous Nephropathy among Black Participants with High-Risk APOL1 Genotype. Clin. J. Am. Soc. Nephrol. 18, 337\u2013343 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"55408_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841\u2013845 (2010).","journal-title":"Science"},{"key":"55408_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.kint.2018.03.017","volume":"94","author":"CD Langefeld","year":"2018","unstructured":"Langefeld, C. D. et al. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions. Kidney Int. 94, 599\u2013607 (2018).","journal-title":"Kidney Int."},{"key":"55408_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ekir.2019.05.007","volume":"4","author":"SA Husain","year":"2019","unstructured":"Husain, S. A. & Chang, J. H. Searching for Second Hits for the Development of APOL1-Associated Kidney Disease. Kidney Int. Rep. 4, 911\u2013913 (2019).","journal-title":"Kidney Int. Rep."},{"key":"55408_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nature01461","volume":"422","author":"L Vanhamme","year":"2003","unstructured":"Vanhamme, L. et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422, 83\u201387 (2003).","journal-title":"Nature"},{"key":"55408_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1126\/science.1114566","volume":"309","author":"D Perez-Morga","year":"2005","unstructured":"Perez-Morga, D. et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309, 469\u2013472 (2005).","journal-title":"Science"},{"key":"55408_CR11","doi-asserted-by":"publisher","first-page":"E2130","DOI":"10.1073\/pnas.1400699111","volume":"111","author":"R Thomson","year":"2014","unstructured":"Thomson, R. et al. Evolution of the primate trypanolytic factor APOL1. Proc. Natl Acad. Sci. USA 111, E2130\u2013E2139 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55408_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0022-2275(20)31171-8","volume":"42","author":"PN Duchateau","year":"2001","unstructured":"Duchateau, P. N., Pullinger, C. R., Cho, M. H., Eng, C. & Kane, J. P. Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J. Lipid Res. 42, 620\u2013630 (2001).","journal-title":"J. Lipid Res."},{"key":"55408_CR13","doi-asserted-by":"publisher","first-page":"424968","DOI":"10.1155\/2012\/424968","volume":"2012","author":"C Bazzi","year":"2012","unstructured":"Bazzi, C., Bakoush, O. & Gesualdo, L. Proteinuria: from molecular to clinical applications in glomerulonephritis. Int J. Nephrol. 2012, 424968 (2012).","journal-title":"Int J. Nephrol."},{"key":"55408_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nm.4287","volume":"23","author":"P Beckerman","year":"2017","unstructured":"Beckerman, P. et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat. Med. 23, 429\u2013438 (2017).","journal-title":"Nat. Med."},{"key":"55408_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ki.2014.270","volume":"87","author":"B Nichols","year":"2015","unstructured":"Nichols, B. et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 87, 332\u2013342 (2015).","journal-title":"Kidney Int."},{"key":"55408_CR16","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1073\/pnas.1421953112","volume":"112","author":"R Thomson","year":"2015","unstructured":"Thomson, R. & Finkelstein, A. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. Proc. Natl Acad. Sci. USA 112, 2894\u20132899 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55408_CR17","doi-asserted-by":"publisher","first-page":"13138","DOI":"10.1074\/jbc.RA120.014201","volume":"295","author":"C Schaub","year":"2020","unstructured":"Schaub, C. et al. Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-lining residues within the C-terminal domain. J. Biol. Chem. 295, 13138\u201313149 (2020).","journal-title":"J. Biol. Chem."},{"key":"55408_CR18","doi-asserted-by":"crossref","unstructured":"Gupta, N. et al. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression. Sci Rep. 14, 3765 (2024).","DOI":"10.1038\/s41598-024-53298-4"},{"key":"55408_CR19","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1681\/ASN.2016050567","volume":"28","author":"L Ma","year":"2017","unstructured":"Ma, L. et al. APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction. J. Am. Soc. Nephrol. 28, 1093\u20131105 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55408_CR20","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1681\/ASN.2016111220","volume":"28","author":"D Granado","year":"2017","unstructured":"Granado, D. et al. Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion. J. Am. Soc. Nephrol. 28, 3227\u20133238 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55408_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1073\/pnas.1522913113","volume":"113","author":"OA Olabisi","year":"2016","unstructured":"Olabisi, O. A. et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc. Natl Acad. Sci. USA 113, 830\u2013837 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55408_CR22","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1056\/NEJMoa063265","volume":"355","author":"B Vanhollebeke","year":"2006","unstructured":"Vanhollebeke, B. et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N. Engl. J. Med. 355, 2752\u20132756 (2006).","journal-title":"N. Engl. J. Med."},{"key":"55408_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molbiopara.2004.07.004","volume":"138","author":"EB Lugli","year":"2004","unstructured":"Lugli, E. B., Pouliot, M., Portela Mdel, P., Loomis, M. R. & Raper, J. Characterization of primate trypanosome lytic factors. Mol. Biochem. Parasitol. 138, 9\u201320 (2004).","journal-title":"Mol. Biochem. Parasitol."},{"key":"55408_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1550-7408.1990.tb01163.x","volume":"37","author":"JR Seed","year":"1990","unstructured":"Seed, J. R., Sechelski, J. B. & Loomis, M. R. A survey for a trypanocidal factor in primate sera. J. Protozool. 37, 393\u2013400 (1990).","journal-title":"J. Protozool."},{"key":"55408_CR25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna, O. et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N. Engl. J. Med 388, 969\u2013979 (2023).","journal-title":"N. Engl. J. Med"},{"key":"55408_CR26","doi-asserted-by":"publisher","unstructured":"McCarthy, G. M. et al. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease. Dis. Model Mech. 14, https:\/\/doi.org\/10.1242\/dmm.048952 (2021).","DOI":"10.1242\/dmm.048952"},{"key":"55408_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00424-022-02767-8","volume":"475","author":"DH Vandorpe","year":"2023","unstructured":"Vandorpe, D. H. et al. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes. Pflug. Arch. 475, 323\u2013341 (2023).","journal-title":"Pflug. Arch."},{"key":"55408_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1681\/ASN.2016121322","volume":"29","author":"JF O\u2019Toole","year":"2018","unstructured":"O\u2019Toole, J. F. et al. ApoL1 Overexpression Drives Variant-Independent Cytotoxicity. J. Am. Soc. Nephrol. 29, 869\u2013879 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55408_CR29","doi-asserted-by":"publisher","first-page":"F463","DOI":"10.1152\/ajprenal.00233.2019","volume":"317","author":"V Kumar","year":"2019","unstructured":"Kumar, V. & Singhal, P. C. APOL1 and kidney cell function. Am. J. Physiol. Ren. Physiol. 317, F463\u2013F477 (2019).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"55408_CR30","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1073\/pnas.96.14.7962","volume":"96","author":"V Ruotsalainen","year":"1999","unstructured":"Ruotsalainen, V. et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc. Natl Acad. Sci. USA 96, 7962\u20137967 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"55408_CR31","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.jpi.2022.100129","volume":"13","author":"A Akatsuka","year":"2022","unstructured":"Akatsuka, A., Horai, Y. & Akatsuka, A. Automated recognition of glomerular lesions in the kidneys of mice by using deep learning. J. Pathol. Inf. 13, 100129 (2022).","journal-title":"J. Pathol. Inf."},{"key":"55408_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1681\/ASN.2020050597","volume":"32","author":"N Bouteldja","year":"2021","unstructured":"Bouteldja, N. et al. Deep Learning-Based Segmentation and Quantification in Experimental Kidney Histopathology. J. Am. Soc. Nephrol. 32, 52\u201368 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55408_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11553-x","volume":"7","author":"F Siegerist","year":"2017","unstructured":"Siegerist, F. et al. Structured illumination microscopy and automatized image processing as a rapid diagnostic tool for podocyte effacement. Sci. Rep. 7, 11473 (2017).","journal-title":"Sci. Rep."},{"key":"55408_CR34","doi-asserted-by":"publisher","unstructured":"Giovinazzo, J. A. et al. Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity. Elife 9, https:\/\/doi.org\/10.7554\/eLife.51185 (2020).","DOI":"10.7554\/eLife.51185"},{"key":"55408_CR35","doi-asserted-by":"publisher","unstructured":"Datta, S. et al. APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci172262 (2024).","DOI":"10.1172\/jci172262"},{"key":"55408_CR36","doi-asserted-by":"publisher","unstructured":"Hung, A. M. et al. Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000000000219 (2023).","DOI":"10.1681\/ASN.0000000000000219"},{"key":"55408_CR37","doi-asserted-by":"publisher","first-page":"12347","DOI":"10.3390\/s120912347","volume":"12","author":"SN Rampersad","year":"2012","unstructured":"Rampersad, S. N. Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sens. (Basel) 12, 12347\u201312360 (2012).","journal-title":"Sens. (Basel)"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55408-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:09:05Z","timestamp":1735852145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-55408-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["55408"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-55408-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3922092\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing financial interest(s): All authors listed are current or past employees of Vertex Pharmaceuticals, Incorporated and may hold stock in the company. Compound 2, Compound 3 and VX-147 are disclosed and claimed in granted U.S. Patent No. 11,618,746 B2, among other places, where Vertex Pharmaceuticals Incorporated is the applicant. The inventors on the patent are as follows: Jingrong Cao, Jon H. Come, Leslie A. Dakin, Francois Denis, Warren A. Dorsch, Anne Fortier, Martine Hamel, Elaine B. Krueger, Brian Ledford, Suganthini S. Nanthakumar, Olivier Nicolas, Camil Sayegh, Timothy J. Senter, Tiansheng Wang, Michael Brodney, Kan-Nian Hu, Peter Rose, Kevin Gagnon, Yi Shi, Muna Shrestha, Ales Medek, Faith Witkos. The aspects covered in the manuscript that are found in the patent application are Compound 2, Compound 3 and VX-147, in addition to the thallium flux and trypanosome rescue assay and their use in discovering these inhibitors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}